<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00673101</url>
  </required_header>
  <id_info>
    <org_study_id>05-07</org_study_id>
    <nct_id>NCT00673101</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of FibroScan in Patients Treated With Methotrexate</brief_title>
  <acronym>Methoscan</acronym>
  <official_title>Evaluation of Liver Fibrosis Using FibroScan and Non-invasive Biochemical Markers in Patients Treated With Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association HGE CHU Bordeaux Sud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association HGE CHU Bordeaux Sud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate liver fibrosis using FibroScan and biochemical markers
      in patients treated with methotrexate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methotrexate (MTX) is an effective treatment for induction of remission and maintenance in
      patients with Crohn's disease, rheumatoid arthritis, or psoriasis which may induce liver
      fibrosis with high cumulative doses. Transient elastography (FibroScan) is a new non-invasive
      rapid, reproducible and bed-side method, allowing assessment of liver fibrosis by measurement
      of liver stiffness. A preliminary study (Laharie et al, Alimentary Pharmaceutical
      Therapeutics 2006) had shown that significant liver fibrosis was rare in Crohn's disease
      patients treated with a high dose of methotrexate. FibroScan was a reliable non-invasive
      method to detect liver fibrosis which could be recommended in these patients. Therefore,
      liver biopsy could be performed only with patients with high FibroScan values and/or with
      chronic liver enzymes abnormalities. However, further longitudinal and prospective studies
      are mandatory to confirm these preliminary data, in patients with crohn's disease but also
      with rheumatoid arthritis and psoriasis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Liver Fibrosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated by Methotrexate
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects, ≥18 years of age.

          -  Patient treated with Methotrexate.

          -  Written informed consent

        Exclusion Criteria:

          -  Patients refusing to participate to the study and to provide written informed consent

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Schaeverbeke, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edouard Chabrun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastroenterology and Hepatology Unit, Haut-Lévêque Hospital, 33604 Pessac, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Hubiche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Sylvie Doutre, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maïté Longy-Boursier, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Bodeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Luc Pellegrin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juliette Foucher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastroenterology and Hepatology Unit, Haut-Lévêque Hospital, 33604 Pessac, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franck Zerbib, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastroenterology and Hepatology Unit, Saint-André Hospital, 33075 Bordeaux, Cedex, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Laharie, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>CHU Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital du Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Laharie, MD, PhD</last_name>
      <phone>33-557-656-439</phone>
      <email>david.laharie@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2008</study_first_submitted>
  <study_first_submitted_qc>May 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Association HGE CHU Bordeaux Sud</investigator_affiliation>
    <investigator_full_name>de Ledinghen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>liver fibrosis, cirrhosis</keyword>
  <keyword>FibroScan</keyword>
  <keyword>transient elastography</keyword>
  <keyword>elastometry</keyword>
  <keyword>methotrexate</keyword>
  <keyword>non invasive blood markers</keyword>
  <keyword>FibroTest</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

